LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

Home・Akcijų sąrašas・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

12.57 1.45

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.15

Max

12.57

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.8M 22M
Pardavimai	7.5M 70M
P/E Sektoriaus vid.	29.791 35.293
Pelno marža	30.729
Darbuotojai	130
EBITDA	6.3M 28M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	-4.15% downside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	485M 1.7B
Ankstesnė atidarymo kaina	11.12
Ankstesnė uždarymo kaina	12.57

Naujienos nuotaikos

By Acuity

26%

74%

63 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

8.1 / 8.21 Palaikymas ir pasipriešinimas

Aurinia Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-17 23:01; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025-09-17 22:48; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025-09-17 21:59; UTC

Uždarbis

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025-09-17 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-09-17 23:39; UTC

Rinkos pokalbiai

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025-09-17 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025-09-17 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025-09-17 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025-09-17 21:00; UTC

Uždarbis

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025-09-17 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-09-17 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 19:59; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025-09-17 19:07; UTC

Rinkos pokalbiai

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025-09-17 18:43; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025-09-17 18:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025-09-17 18:20; UTC

Rinkos pokalbiai

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 18:18; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025-09-17 18:14; UTC

Rinkos pokalbiai

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025-09-17 17:59; UTC

Rinkos pokalbiai

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025-09-17 17:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025-09-17 17:06; UTC

Įsigijimai, susijungimai, perėmimai

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025-09-17 16:51; UTC

Uždarbis

Correct: Exor 1H Net Loss -EUR624M

2025-09-17 16:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-17 16:34; UTC

Rinkos pokalbiai

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025-09-17 16:25; UTC

Uždarbis

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025-09-17 16:23; UTC

Uždarbis

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Akcijų palyginimas

Kainos pokytis

Aurinia Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-4.15% į apačią

12 mėnesių prognozė

Vidutinis 12 USD -4.15%

Aukščiausias 17 USD

Žemiausias 9 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Aurinia Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Aurinia Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.1 / 8.21Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Rinkos nuotaikos

By Acuity

63 / 371 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.